|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Apr 2026 |
4,991 |
34,939
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. |
07 Apr 2026 |
4,991 |
471,214
(0%)
|
0%
|
146.3 |
730,383
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Sale of securities on an exchange or to another person at price $ 225.50 per share. |
07 Apr 2026 |
4,991 |
466,223
(0%)
|
0%
|
225.5 |
1,125,486
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 224.31 per share. |
01 Apr 2026 |
1,000 |
83,495
(0%)
|
0%
|
224.3 |
224,310
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 225.00 per share. |
01 Apr 2026 |
2,000 |
60,773
(0%)
|
0%
|
225 |
450,000
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. |
09 Mar 2026 |
4,991 |
471,214
(0%)
|
0%
|
146.3 |
730,383
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Sale of securities on an exchange or to another person at price $ 251.03 per share. |
09 Mar 2026 |
4,991 |
466,223
(0%)
|
0%
|
251.0 |
1,252,902
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Mar 2026 |
4,991 |
39,930
|
-
|
|
-
|
ResMed Common Stock Options |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 260.22 per share. |
04 Mar 2026 |
2,000 |
62,773
(0%)
|
0%
|
260.2 |
520,440
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 254.30 per share. |
02 Mar 2026 |
1,000 |
84,495
(0%)
|
0%
|
254.3 |
254,300
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. |
09 Feb 2026 |
4,991 |
471,214
(0%)
|
0%
|
146.3 |
730,383
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Sale of securities on an exchange or to another person at price $ 273.78 per share. |
09 Feb 2026 |
4,991 |
466,223
(0%)
|
0%
|
273.8 |
1,366,436
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Feb 2026 |
4,991 |
44,921
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 260.00 per share. |
04 Feb 2026 |
50 |
9,691
(0%)
|
0%
|
260 |
13,000
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 251.31 per share. |
04 Feb 2026 |
2,000 |
64,773
(0%)
|
0%
|
251.3 |
502,620
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 257.03 per share. |
02 Feb 2026 |
1,000 |
85,495
(0%)
|
0%
|
257.0 |
257,030
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. |
07 Jan 2026 |
4,991 |
471,214
(0%)
|
0%
|
146.3 |
730,383
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 248.83 per share. |
07 Jan 2026 |
2,000 |
66,773
(0%)
|
0%
|
248.8 |
497,660
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Sale of securities on an exchange or to another person at price $ 248.46 per share. |
07 Jan 2026 |
4,991 |
466,223
(0%)
|
0%
|
248.5 |
1,240,065
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Jan 2026 |
4,991 |
49,912
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 241.75 per share. |
02 Jan 2026 |
1,000 |
86,495
(0%)
|
0%
|
241.8 |
241,750
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 241.76 per share. |
02 Jan 2026 |
50 |
9,741
(0%)
|
0%
|
241.8 |
12,088
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Sale of securities on an exchange or to another person at price $ 251.41 per share. |
08 Dec 2025 |
4,991 |
466,223
(0%)
|
0%
|
251.4 |
1,254,796
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Dec 2025 |
4,991 |
54,903
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. |
08 Dec 2025 |
4,991 |
471,214
(0%)
|
0%
|
146.3 |
730,383
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 251.47 per share. |
03 Dec 2025 |
2,000 |
68,773
(0%)
|
0%
|
251.5 |
502,940
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 244.16 per share. |
01 Dec 2025 |
50 |
9,791
(0%)
|
0%
|
244.2 |
12,208
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 244.16 per share. |
01 Dec 2025 |
1,000 |
87,495
(0%)
|
0%
|
244.2 |
244,160
|
ResMed Common Stock |
|
Witte Jan De
|
Director |
Sale of securities on an exchange or to another person at price $ 255.00 per share. |
25 Nov 2025 |
2,055 |
4,261
(0%)
|
0%
|
255 |
524,025
|
ReMed Common Stock |
|
Nicole Mowad-Nassar
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 Nov 2025 |
1,331 |
1,331
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 Nov 2025 |
33,288 |
33,288
|
-
|
|
-
|
ResMed Common Stock Options |
|
Peter C. Farrell
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 Nov 2025 |
1,331 |
1,331
|
-
|
|
-
|
ResMed Common Stock Options |
|
Justin Leong
|
Chief Product Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
1,848 |
29,028
(0%)
|
0%
|
|
0
|
ReMed Common Stock |
|
Christopher J. DelOrefice
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
1,073 |
2,423
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
John Hernandez
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
1,073 |
5,118
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Desney Tan
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
1,073 |
6,002
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Nicole Mowad-Nassar
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
536 |
777
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Witte Jan De
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
1,073 |
6,316
(0%)
|
0%
|
|
0
|
ReMed Common Stock |
|
Harjit Gill
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
1,073 |
10,940
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
536 |
70,773
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Ronald R. Taylor
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
1,073 |
24,771
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
2,710 |
88,495
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
13,551 |
473,520
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. |
20 Nov 2025 |
7,297 |
466,223
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Carol J. Burt
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
1,073 |
2,156
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Karen Drexler
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2025 |
1,073 |
10,602
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
14 Nov 2025 |
11,442 |
77,552
(0%)
|
0%
|
101.6 |
1,162,965
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
14 Nov 2025 |
11,442 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Peter C. Farrell
|
Director |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.46 per share. |
14 Nov 2025 |
7,314 |
70,238
(0%)
|
0%
|
244.5 |
1,787,980
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 251.57 per share. |
11 Nov 2025 |
162 |
68,110
(0%)
|
0%
|
251.6 |
40,755
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 250.27 per share. |
11 Nov 2025 |
715 |
10,342
(0%)
|
0%
|
250.3 |
178,944
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 251.15 per share. |
11 Nov 2025 |
173 |
11,057
(0%)
|
0%
|
251.2 |
43,449
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 250.24 per share. |
11 Nov 2025 |
135 |
11,231
(0%)
|
0%
|
250.2 |
33,782
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 250.47 per share. |
11 Nov 2025 |
500 |
9,841
(0%)
|
0%
|
250.5 |
125,234
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 252.05 per share. |
11 Nov 2025 |
2,000 |
66,110
(0%)
|
0%
|
252.1 |
504,100
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 250.16 per share. |
11 Nov 2025 |
2,231 |
465,634
(0%)
|
0%
|
250.2 |
558,109
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 250.18 per share. |
11 Nov 2025 |
2,205 |
459,969
(0%)
|
0%
|
250.2 |
551,645
|
ResMed Common Stock |
|
Harjit Gill
|
Director |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 251.47 per share. |
11 Nov 2025 |
38 |
9,867
(0%)
|
0%
|
251.5 |
9,556
|
ResMed Common Stock |
|
Witte Jan De
|
Director |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 251.58 per share. |
11 Nov 2025 |
76 |
5,242
(0%)
|
0%
|
251.6 |
19,120
|
ReMed Common Stock |
|
Witte Jan De
|
Director |
Sale of securities on an exchange or to another person at price $ 250.25 per share. |
11 Nov 2025 |
487 |
5,319
(0%)
|
0%
|
250.3 |
121,872
|
ReMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 250.12 per share. |
11 Nov 2025 |
3,459 |
462,175
(0%)
|
0%
|
250.1 |
865,177
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Nov 2025 |
7,028 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
07 Nov 2025 |
983 |
468,849
(0%)
|
0%
|
101.6 |
99,912
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Nov 2025 |
983 |
7,028
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Sale of securities on an exchange or to another person at price $ 249.75 per share. |
07 Nov 2025 |
8,011 |
467,866
(0%)
|
0%
|
249.8 |
2,000,773
|
ResMed Common Stock |
|
Michael J. Farrell
|
Director, Chairman and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
07 Nov 2025 |
7,028 |
475,877
(0%)
|
0%
|
101.6 |
714,326
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 247.54 per share. |
03 Nov 2025 |
3,000 |
85,745
(0%)
|
0%
|
247.5 |
742,620
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
03 Nov 2025 |
2,000 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
03 Nov 2025 |
2,000 |
88,745
(0%)
|
0%
|
101.6 |
203,280
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 282.85 per share. |
07 Oct 2025 |
8,009 |
467,792
(0%)
|
0%
|
282.8 |
2,265,332
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Oct 2025 |
8,009 |
8,011
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
07 Oct 2025 |
8,009 |
475,801
(0%)
|
0%
|
101.6 |
814,035
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 274.36 per share. |
01 Oct 2025 |
100 |
11,327
(0%)
|
0%
|
274.4 |
27,436
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
01 Oct 2025 |
2,000 |
2,000
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 274.36 per share. |
01 Oct 2025 |
3,000 |
86,745
(0%)
|
0%
|
274.4 |
823,080
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
01 Oct 2025 |
2,000 |
89,745
(0%)
|
0%
|
101.6 |
203,280
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 278.14 per share. |
08 Sep 2025 |
8,009 |
467,792
(0%)
|
0%
|
278.1 |
2,227,590
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
08 Sep 2025 |
8,009 |
475,801
(0%)
|
0%
|
101.6 |
814,035
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Sep 2025 |
8,009 |
16,020
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 270.77 per share. |
02 Sep 2025 |
3,000 |
87,745
(0%)
|
0%
|
270.8 |
812,310
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
02 Sep 2025 |
2,000 |
4,000
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
02 Sep 2025 |
2,000 |
90,745
(0%)
|
0%
|
101.6 |
203,280
|
ResMed Common Stock |
|
Nicole Mowad-Nassar
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Sep 2025 |
241 |
241
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
John Hernandez
|
Director |
Sale of securities on an exchange or to another person at price $ 287.10 per share. |
18 Aug 2025 |
2,575 |
4,045
(0%)
|
0%
|
287.1 |
739,289
|
ResMed Common Stock |
|
John Hernandez
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
18 Aug 2025 |
2,575 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
John Hernandez
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 148.90 per share. |
18 Aug 2025 |
2,575 |
6,620
(0%)
|
0%
|
148.9 |
383,418
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2025 |
5,462 |
88,745
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2025 |
12,289 |
467,792
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Justin Leong
|
Chief Product Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2025 |
5,462 |
27,180
(0%)
|
0%
|
|
0
|
ReMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2025 |
2,941 |
11,427
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Aug 2025 |
8,009 |
24,029
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 279.48 per share. |
07 Aug 2025 |
8,009 |
455,503
(0%)
|
0%
|
279.5 |
2,238,379
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
07 Aug 2025 |
8,009 |
463,512
(0%)
|
0%
|
101.6 |
814,035
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
01 Aug 2025 |
2,000 |
6,000
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 281.90 per share. |
01 Aug 2025 |
3,000 |
83,283
(0%)
|
0%
|
281.9 |
845,700
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
01 Aug 2025 |
2,000 |
86,283
(0%)
|
0%
|
101.6 |
203,280
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 281.90 per share. |
01 Aug 2025 |
50 |
8,486
(0%)
|
0%
|
281.9 |
14,095
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
07 Jul 2025 |
8,009 |
463,512
(0%)
|
0%
|
101.6 |
814,035
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 256.72 per share. |
07 Jul 2025 |
8,009 |
455,503
(0%)
|
0%
|
256.7 |
2,056,076
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Jul 2025 |
8,009 |
32,038
|
-
|
|
-
|
ResMed Common Stock Options |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 255.49 per share. |
02 Jul 2025 |
945 |
68,273
(0%)
|
0%
|
255.5 |
241,438
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 256.98 per share. |
01 Jul 2025 |
66 |
8,536
(0%)
|
0%
|
257.0 |
16,961
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
01 Jul 2025 |
1,966 |
8,917
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 256.99 per share. |
01 Jul 2025 |
3,883 |
84,283
(0%)
|
0%
|
257.0 |
997,892
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
01 Jul 2025 |
917 |
88,166
(0%)
|
0%
|
101.6 |
93,204
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
01 Jul 2025 |
1,966 |
87,249
(0%)
|
0%
|
101.6 |
199,824
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
01 Jul 2025 |
917 |
8,000
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Jun 2025 |
8,009 |
40,047
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 251.21 per share. |
09 Jun 2025 |
8,009 |
455,503
(0%)
|
0%
|
251.2 |
2,011,910
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
09 Jun 2025 |
8,009 |
463,512
(0%)
|
0%
|
101.6 |
814,035
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 247.32 per share. |
04 Jun 2025 |
2,000 |
69,218
(0%)
|
0%
|
247.3 |
494,640
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 243.78 per share. |
02 Jun 2025 |
1,000 |
85,283
(0%)
|
0%
|
243.8 |
243,780
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 243.78 per share. |
02 Jun 2025 |
41 |
8,870
(0%)
|
0%
|
243.8 |
9,995
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 245.01 per share. |
02 Jun 2025 |
267 |
8,603
(0%)
|
0%
|
245.0 |
65,419
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 244.59 per share. |
22 May 2025 |
3,644 |
86,283
(0%)
|
0%
|
244.6 |
891,286
|
ResMed Common Stock |
|
Witte Jan De
|
Director |
Sale of securities on an exchange or to another person at price $ 243.47 per share. |
20 May 2025 |
2,000 |
5,806
(0%)
|
0%
|
243.5 |
486,940
|
ReMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 242.25 per share. |
07 May 2025 |
2,000 |
71,218
(0%)
|
0%
|
242.3 |
484,500
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 May 2025 |
8,009 |
48,056
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 243.23 per share. |
07 May 2025 |
8,009 |
455,503
(0%)
|
0%
|
243.2 |
1,948,003
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
07 May 2025 |
8,009 |
463,512
(0%)
|
0%
|
101.6 |
814,035
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 215.58 per share. |
08 Apr 2025 |
1,000 |
89,864
(0%)
|
0%
|
215.6 |
215,580
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Apr 2025 |
8,009 |
56,065
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
07 Apr 2025 |
8,009 |
463,482
(0%)
|
0%
|
101.6 |
814,035
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 209.85 per share. |
07 Apr 2025 |
8,009 |
455,472
(0%)
|
0%
|
209.9 |
1,680,699
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 219.74 per share. |
02 Apr 2025 |
2,000 |
73,218
(0%)
|
0%
|
219.7 |
439,480
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 222.86 per share. |
01 Apr 2025 |
64 |
8,846
(0%)
|
0%
|
222.9 |
14,263
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Sale of securities on an exchange or to another person at price $ 239.31 per share. |
10 Mar 2025 |
9,745 |
9,725
(0%)
|
0%
|
239.3 |
2,332,096
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 211.76 per share. |
10 Mar 2025 |
5,882 |
19,470
(0%)
|
0%
|
211.8 |
1,245,572
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. |
10 Mar 2025 |
3,589 |
13,588
(0%)
|
0%
|
146.3 |
525,214
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. |
10 Mar 2025 |
169 |
9,894
(0%)
|
0%
|
146.3 |
24,731
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
10 Mar 2025 |
3,589 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
10 Mar 2025 |
5,882 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
10 Mar 2025 |
105 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
10 Mar 2025 |
169 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 211.76 per share. |
10 Mar 2025 |
105 |
9,999
(0%)
|
0%
|
211.8 |
22,235
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 230.36 per share. |
10 Mar 2025 |
1,000 |
90,864
(0%)
|
0%
|
230.4 |
230,360
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Mar 2025 |
8,009 |
64,074
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 229.20 per share. |
07 Mar 2025 |
8,009 |
455,472
(0%)
|
0%
|
229.2 |
1,835,692
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
07 Mar 2025 |
8,009 |
463,481
(0%)
|
0%
|
101.6 |
814,035
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 227.71 per share. |
05 Mar 2025 |
2,000 |
75,218
(0%)
|
0%
|
227.7 |
455,420
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
03 Mar 2025 |
4,726 |
5,882
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 211.76 per share. |
03 Mar 2025 |
367 |
10,092
(0%)
|
0%
|
211.8 |
77,716
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. |
03 Mar 2025 |
3,506 |
13,598
(0%)
|
0%
|
146.3 |
513,068
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. |
03 Mar 2025 |
514 |
14,112
(0%)
|
0%
|
146.3 |
75,219
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 211.76 per share. |
03 Mar 2025 |
4,726 |
18,838
(0%)
|
0%
|
211.8 |
1,000,778
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Sale of securities on an exchange or to another person at price $ 235.25 per share. |
03 Mar 2025 |
367 |
18,471
(0%)
|
0%
|
235.2 |
86,336
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Sale of securities on an exchange or to another person at price $ 235.40 per share. |
03 Mar 2025 |
3,506 |
14,965
(0%)
|
0%
|
235.4 |
825,308
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Sale of securities on an exchange or to another person at price $ 235.25 per share. |
03 Mar 2025 |
514 |
14,451
(0%)
|
0%
|
235.2 |
120,918
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Sale of securities on an exchange or to another person at price $ 235.43 per share. |
03 Mar 2025 |
4,726 |
9,725
(0%)
|
0%
|
235.4 |
1,112,624
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
03 Mar 2025 |
367 |
105
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
03 Mar 2025 |
3,506 |
3,589
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
03 Mar 2025 |
514 |
169
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 234.09 per share. |
03 Mar 2025 |
64 |
8,910
(0%)
|
0%
|
234.1 |
14,982
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 238.98 per share. |
10 Feb 2025 |
1,000 |
91,864
(0%)
|
0%
|
239.0 |
238,980
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 236.77 per share. |
07 Feb 2025 |
8,009 |
455,472
(0%)
|
0%
|
236.8 |
1,896,307
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
07 Feb 2025 |
8,009 |
463,481
(0%)
|
0%
|
101.6 |
814,035
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Feb 2025 |
8,009 |
72,083
|
-
|
|
-
|
ResMed Common Stock Options |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 242.11 per share. |
05 Feb 2025 |
2,000 |
77,218
(0%)
|
0%
|
242.1 |
484,220
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 242.42 per share. |
03 Feb 2025 |
64 |
8,974
(0%)
|
0%
|
242.4 |
15,515
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 230.99 per share. |
02 Jan 2025 |
2,000 |
79,218
(0%)
|
0%
|
231.0 |
461,980
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 230.99 per share. |
02 Jan 2025 |
75 |
9,038
(0%)
|
0%
|
231.0 |
17,324
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 244.23 per share. |
09 Dec 2024 |
1,000 |
93,864
(0%)
|
0%
|
244.2 |
244,230
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 245.65 per share. |
04 Dec 2024 |
2,000 |
81,218
(0%)
|
0%
|
245.7 |
491,300
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 248.91 per share. |
29 Nov 2024 |
74 |
9,113
(0%)
|
0%
|
248.9 |
18,419
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Gift of securities by or to the insider at price $ 0.00 per share. |
29 Nov 2024 |
173 |
9,187
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 Nov 2024 |
1,468 |
1,468
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 249.66 per share. |
25 Nov 2024 |
2,000 |
0
(0%)
|
0%
|
249.7 |
499,330
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Gift of securities by or to the insider at price $ 0.00 per share. |
25 Nov 2024 |
2,000 |
2,090
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Gift of securities by or to the insider at price $ 0.00 per share. |
25 Nov 2024 |
2,000 |
2,000
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 Nov 2024 |
33,036 |
33,036
|
-
|
|
-
|
ResMed Common Stock Options |
|
Justin Leong
|
Chief Product Officer |
Sale of securities on an exchange or to another person at price $ 243.09 per share. |
22 Nov 2024 |
6,160 |
21,718
(0%)
|
0%
|
243.1 |
1,497,416
|
ReMed Common Stock |
|
Peter C. Farrell
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2024 |
542 |
83,218
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Ronald R. Taylor
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2024 |
1,083 |
23,698
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Richard Sulpizio
|
Director |
|
20 Nov 2024 |
1,083 |
17,796
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Carol J. Burt
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2024 |
1,083 |
2,851
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Karen Drexler
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2024 |
1,083 |
9,529
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Harjit Gill
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2024 |
1,083 |
9,905
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Witte Jan De
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2024 |
1,083 |
7,806
(0%)
|
0%
|
|
0
|
ReMed Common Stock |
|
Christopher DelOrefice
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2024 |
1,083 |
1,350
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
John Hernandez
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2024 |
1,083 |
4,045
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Desney Tan
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Nov 2024 |
1,083 |
4,929
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Witte Jan De
|
Director |
Sale of securities on an exchange or to another person at price $ 248.81 per share. |
12 Nov 2024 |
796 |
6,723
(0%)
|
0%
|
248.8 |
198,053
|
ReMed Common Stock |
|
Peter C. Farrell
|
Director |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.81 per share. |
11 Nov 2024 |
527 |
82,676
(0%)
|
0%
|
252.8 |
133,233
|
ResMed Common Stock |
|
Harjit Gill
|
Director |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 253.53 per share. |
11 Nov 2024 |
132 |
8,822
(0%)
|
0%
|
253.5 |
33,466
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.54 per share. |
11 Nov 2024 |
1,417 |
9,725
(0%)
|
0%
|
252.5 |
357,856
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.71 per share. |
11 Nov 2024 |
445 |
11,142
(0%)
|
0%
|
252.7 |
112,457
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.41 per share. |
11 Nov 2024 |
603 |
11,588
(0%)
|
0%
|
252.4 |
152,204
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.74 per share. |
11 Nov 2024 |
684 |
9,803
(0%)
|
0%
|
252.7 |
172,875
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 253.93 per share. |
11 Nov 2024 |
136 |
9,360
(0%)
|
0%
|
253.9 |
34,535
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.84 per share. |
11 Nov 2024 |
172 |
9,497
(0%)
|
0%
|
252.8 |
43,488
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.95 per share. |
11 Nov 2024 |
134 |
9,669
(0%)
|
0%
|
252.9 |
33,895
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 249.00 per share. |
08 Nov 2024 |
1,000 |
94,864
(0%)
|
0%
|
249 |
249,000
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.41 per share. |
07 Nov 2024 |
3,101 |
461,152
(0%)
|
0%
|
252.4 |
782,725
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 246.26 per share. |
07 Nov 2024 |
14,683 |
464,254
(0%)
|
0%
|
246.3 |
3,615,821
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. |
07 Nov 2024 |
14,683 |
478,937
(0%)
|
0%
|
85.0 |
1,247,761
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Nov 2024 |
14,683 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.48 per share. |
07 Nov 2024 |
2,226 |
458,925
(0%)
|
0%
|
252.5 |
562,016
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.45 per share. |
07 Nov 2024 |
3,452 |
455,472
(0%)
|
0%
|
252.4 |
871,443
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 248.74 per share. |
06 Nov 2024 |
2,000 |
83,204
(0%)
|
0%
|
248.7 |
497,480
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 242.00 per share. |
01 Nov 2024 |
69 |
10,443
(0%)
|
0%
|
242 |
16,698
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Other type of transaction at price $ 0.00 per share. |
30 Oct 2024 |
9,628 |
9,628
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Other type of transaction at price $ 0.00 per share. |
30 Oct 2024 |
9,628 |
12,160
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
11 Oct 2024 |
4,260 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Sale of securities on an exchange or to another person at price $ 238.48 per share. |
11 Oct 2024 |
4,260 |
21,788
(0%)
|
0%
|
238.5 |
1,015,925
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
11 Oct 2024 |
4,260 |
26,048
(0%)
|
0%
|
101.6 |
432,986
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 233.47 per share. |
08 Oct 2024 |
1,000 |
95,812
(0%)
|
0%
|
233.5 |
233,470
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 231.91 per share. |
07 Oct 2024 |
14,683 |
464,169
(0%)
|
0%
|
231.9 |
3,405,206
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. |
07 Oct 2024 |
14,683 |
478,852
(0%)
|
0%
|
85.0 |
1,247,761
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Oct 2024 |
14,683 |
14,683
|
-
|
|
-
|
ResMed Common Stock Options |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 237.20 per share. |
02 Oct 2024 |
2,000 |
85,204
(0%)
|
0%
|
237.2 |
474,400
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
12 Sep 2024 |
5,000 |
4,260
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Sale of securities on an exchange or to another person at price $ 252.56 per share. |
12 Sep 2024 |
5,000 |
21,788
(0%)
|
0%
|
252.6 |
1,262,800
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
Chief Commercial Officer, SaaS |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
12 Sep 2024 |
5,000 |
26,788
(0%)
|
0%
|
101.6 |
508,200
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 246.42 per share. |
09 Sep 2024 |
1,000 |
96,812
(0%)
|
0%
|
246.4 |
246,420
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 248.38 per share. |
09 Sep 2024 |
14,683 |
464,169
(0%)
|
0%
|
248.4 |
3,646,950
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Sep 2024 |
14,683 |
29,366
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. |
09 Sep 2024 |
14,683 |
478,852
(0%)
|
0%
|
85.0 |
1,247,761
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 239.90 per share. |
04 Sep 2024 |
2,000 |
87,204
(0%)
|
0%
|
239.9 |
479,800
|
ResMed Common Stock |
|
Christopher DelOrefice
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
03 Sep 2024 |
267 |
267
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 231.00 per share. |
20 Aug 2024 |
882 |
10,512
(0%)
|
0%
|
231 |
203,742
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Aug 2024 |
19,272 |
460,071
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Aug 2024 |
4,098 |
464,169
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2024 |
841 |
97,812
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2024 |
7,915 |
96,971
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Justin Leong
|
Chief Product Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2024 |
878 |
27,878
(0%)
|
0%
|
|
0
|
ReMed Common Stock |
|
Justin Leong
|
Chief Product Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2024 |
8,259 |
27,000
(0%)
|
0%
|
|
0
|
ReMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2024 |
841 |
21,788
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2024 |
7,915 |
20,947
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2024 |
476 |
11,394
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Aug 2024 |
4,474 |
10,918
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.80 per share. |
12 Aug 2024 |
2,086 |
15,118
(0%)
|
0%
|
95.8 |
199,839
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
12 Aug 2024 |
1,037 |
9,260
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
President, SaaS Business |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
12 Aug 2024 |
6,877 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
President, SaaS Business |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
12 Aug 2024 |
2,086 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
President, SaaS Business |
Sale of securities on an exchange or to another person at price $ 216.60 per share. |
12 Aug 2024 |
10,000 |
13,032
(0%)
|
0%
|
216.6 |
2,166,000
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
12 Aug 2024 |
1,037 |
23,032
(0%)
|
0%
|
101.6 |
105,401
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.80 per share. |
12 Aug 2024 |
6,877 |
21,995
(0%)
|
0%
|
95.8 |
658,817
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 212.16 per share. |
08 Aug 2024 |
1,000 |
89,056
(0%)
|
0%
|
212.2 |
212,160
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Aug 2024 |
14,683 |
44,049
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 214.25 per share. |
07 Aug 2024 |
14,683 |
440,799
(0%)
|
0%
|
214.3 |
3,145,905
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. |
07 Aug 2024 |
14,683 |
455,482
(0%)
|
0%
|
85.0 |
1,247,761
|
ResMed Common Stock |
|
Justin Leong
|
President, Asia Latin America |
Sale of securities on an exchange or to another person at price $ 217.07 per share. |
05 Aug 2024 |
48,000 |
18,741
(0%)
|
0%
|
217.1 |
10,419,552
|
ReMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 194.35 per share. |
08 Jul 2024 |
1,000 |
90,056
(0%)
|
0%
|
194.4 |
194,350
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Jul 2024 |
14,683 |
58,732
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 192.97 per share. |
08 Jul 2024 |
14,683 |
440,799
(0%)
|
0%
|
193.0 |
2,833,330
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. |
08 Jul 2024 |
14,683 |
455,482
(0%)
|
0%
|
85.0 |
1,247,761
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 209.81 per share. |
10 Jun 2024 |
1,000 |
91,056
(0%)
|
0%
|
209.8 |
209,810
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Jun 2024 |
14,683 |
73,415
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. |
07 Jun 2024 |
14,683 |
455,482
(0%)
|
0%
|
85.0 |
1,247,761
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 211.66 per share. |
07 Jun 2024 |
14,683 |
440,799
(0%)
|
0%
|
211.7 |
3,107,739
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 206.52 per share. |
04 Jun 2024 |
267 |
6,444
(0%)
|
0%
|
206.5 |
55,140
|
ResMed Common Stock |
|
Carol J. Burt
|
Director |
Gift of securities by or to the insider at price $ 0.00 per share. |
24 May 2024 |
47 |
14,892
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Gift of securities by or to the insider at price $ 0.00 per share. |
15 May 2024 |
68,200 |
89,204
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Witte Jan De
|
Director |
Sale of securities on an exchange or to another person at price $ 218.29 per share. |
15 May 2024 |
360 |
7,519
(0%)
|
0%
|
218.3 |
78,584
|
ReMed Common Stock |
|
Witte Jan De
|
Director |
Sale of securities on an exchange or to another person at price $ 218.29 per share. |
15 May 2024 |
360 |
7,519
(0%)
|
0%
|
218.3 |
78,584
|
ReMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. |
08 May 2024 |
12,000 |
105,056
(0%)
|
0%
|
101.6 |
1,219,680
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 May 2024 |
12,000 |
10,883
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 211.37 per share. |
08 May 2024 |
13,000 |
92,056
(0%)
|
0%
|
211.4 |
2,747,810
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 May 2024 |
13,507 |
88,098
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. |
07 May 2024 |
1,176 |
441,928
(0%)
|
0%
|
85.0 |
99,936
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. |
07 May 2024 |
13,507 |
455,435
(0%)
|
0%
|
85.0 |
1,147,825
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 216.50 per share. |
07 May 2024 |
14,683 |
440,752
(0%)
|
0%
|
216.5 |
3,178,815
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 May 2024 |
1,176 |
101,605
|
-
|
|
-
|
ResMed Common Stock Options |
|
Karen Drexler
|
Director |
Sale of securities on an exchange or to another person at price $ 214.92 per share. |
29 Apr 2024 |
425 |
8,446
(0%)
|
0%
|
214.9 |
91,341
|
ResMed Common Stock |
|
Carol J. Burt
|
Director |
Gift of securities by or to the insider at price $ 0.00 per share. |
29 Apr 2024 |
234 |
14,939
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 180.00 per share. |
04 Mar 2024 |
81 |
6,607
(0%)
|
0%
|
180 |
14,580
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 173.25 per share. |
01 Mar 2024 |
200 |
6,688
(0%)
|
0%
|
173.3 |
34,650
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 152.62 per share. |
27 Nov 2023 |
3,000 |
92,962
(0%)
|
0%
|
152.6 |
457,860
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Gift of securities by or to the insider at price $ 0.00 per share. |
22 Nov 2023 |
72 |
6,888
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 148.96 per share. |
20 Nov 2023 |
1,375 |
13,849
(0%)
|
0%
|
149.0 |
204,825
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.34 per share. |
20 Nov 2023 |
366 |
12,908
(0%)
|
0%
|
149.3 |
54,657
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2023 |
1,768 |
180,939
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Ronald R. Taylor
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2023 |
1,768 |
22,615
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Richard Sulpizio
|
Director |
|
16 Nov 2023 |
1,768 |
16,713
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 148.90 per share. |
16 Nov 2023 |
1,343 |
443,105
(0%)
|
0%
|
148.9 |
199,973
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
16 Nov 2023 |
3,462 |
444,448
(0%)
|
0%
|
57.8 |
199,965
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.00 per share. |
16 Nov 2023 |
2,352 |
440,752
(0%)
|
0%
|
149.0 |
350,445
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
16 Nov 2023 |
3,462 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2023 |
55,468 |
55,468
|
-
|
|
-
|
ResMed Common Stock Options |
|
Carol J. Burt
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2023 |
1,768 |
2,890
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Karen Drexler
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2023 |
884 |
8,871
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Karen Drexler
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2023 |
2,575 |
2,575
|
-
|
|
-
|
ResMed Common Stock Options |
|
Harjit Gill
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2023 |
1,768 |
8,955
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Witte Jan De
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2023 |
1,768 |
7,879
(0%)
|
0%
|
|
0
|
ReMed Common Stock |
|
John Hernandez
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2023 |
884 |
2,962
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
John Hernandez
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2023 |
2,575 |
2,575
|
-
|
|
-
|
ResMed Common Stock Options |
|
Desney Tan
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2023 |
1,768 |
3,846
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Nov 2023 |
5,678 |
3,462
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 152.04 per share. |
15 Nov 2023 |
5,678 |
440,986
(0%)
|
0%
|
152.0 |
863,281
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Nov 2023 |
5,678 |
446,664
(0%)
|
0%
|
57.8 |
327,961
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.77 per share. |
13 Nov 2023 |
325 |
179,171
(0%)
|
0%
|
143.8 |
46,724
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.74 per share. |
13 Nov 2023 |
759 |
15,224
(0%)
|
0%
|
143.7 |
109,099
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.68 per share. |
13 Nov 2023 |
944 |
15,985
(0%)
|
0%
|
143.7 |
135,636
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.62 per share. |
13 Nov 2023 |
2,181 |
440,986
(0%)
|
0%
|
143.6 |
313,233
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.64 per share. |
13 Nov 2023 |
3,037 |
443,167
(0%)
|
0%
|
143.6 |
436,243
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.63 per share. |
13 Nov 2023 |
3,232 |
446,205
(0%)
|
0%
|
143.6 |
464,217
|
ResMed Common Stock |
|
Harjit Gill
|
Director |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.96 per share. |
13 Nov 2023 |
79 |
7,187
(0%)
|
0%
|
144.0 |
11,373
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.78 per share. |
13 Nov 2023 |
590 |
13,711
(0%)
|
0%
|
143.8 |
84,829
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.91 per share. |
13 Nov 2023 |
435 |
13,275
(0%)
|
0%
|
143.9 |
62,601
|
ResMed Common Stock |
|
Lucile Blaise
|
President, Sleep & RC Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.98 per share. |
13 Nov 2023 |
135 |
10,305
(0%)
|
0%
|
144.0 |
19,437
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.60 per share. |
13 Nov 2023 |
91 |
7,308
(0%)
|
0%
|
144.6 |
13,159
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.17 per share. |
13 Nov 2023 |
93 |
6,960
(0%)
|
0%
|
144.2 |
13,408
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.23 per share. |
13 Nov 2023 |
136 |
7,054
(0%)
|
0%
|
144.2 |
19,615
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.30 per share. |
13 Nov 2023 |
117 |
7,190
(0%)
|
0%
|
144.3 |
16,883
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 143.44 per share. |
01 Nov 2023 |
25 |
7,358
(0%)
|
0%
|
143.4 |
3,586
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
16 Oct 2023 |
5,675 |
9,140
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 140.70 per share. |
16 Oct 2023 |
5,675 |
449,360
(0%)
|
0%
|
140.7 |
798,464
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
16 Oct 2023 |
5,675 |
455,035
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 145.92 per share. |
02 Oct 2023 |
25 |
7,383
(0%)
|
0%
|
145.9 |
3,648
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Sep 2023 |
5,675 |
14,815
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 146.35 per share. |
15 Sep 2023 |
5,675 |
449,360
(0%)
|
0%
|
146.3 |
830,514
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Sep 2023 |
5,675 |
455,035
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 161.16 per share. |
01 Sep 2023 |
25 |
7,408
(0%)
|
0%
|
161.2 |
4,029
|
ResMed Common Stock |
|
Lucile Blaise
|
President, Sleep & RC Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 165.97 per share. |
25 Aug 2023 |
379 |
10,355
(0%)
|
0%
|
166.0 |
62,903
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 Aug 2023 |
4,972 |
95,915
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 Aug 2023 |
12,430 |
449,360
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 Aug 2023 |
2,486 |
14,273
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Lucile Blaise
|
President, Sleep & RC Business |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 Aug 2023 |
819 |
7,441
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Lucile Blaise
|
President, Sleep & RC Business |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 Aug 2023 |
3,294 |
10,735
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 Aug 2023 |
2,247 |
7,433
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 181.01 per share. |
15 Aug 2023 |
1,500 |
250,526
(0%)
|
0%
|
181.0 |
271,515
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Aug 2023 |
5,675 |
20,490
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 183.20 per share. |
15 Aug 2023 |
5,675 |
436,930
(0%)
|
0%
|
183.2 |
1,039,647
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Aug 2023 |
5,675 |
442,605
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 224.12 per share. |
01 Aug 2023 |
25 |
5,186
(0%)
|
0%
|
224.1 |
5,603
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 222.22 per share. |
17 Jul 2023 |
1,500 |
252,026
(0%)
|
0%
|
222.2 |
333,330
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Jul 2023 |
5,675 |
26,165
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 221.27 per share. |
17 Jul 2023 |
5,675 |
436,930
(0%)
|
0%
|
221.3 |
1,255,686
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
17 Jul 2023 |
5,675 |
442,605
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Sale of securities on an exchange or to another person at price $ 220.00 per share. |
13 Jul 2023 |
500 |
11,787
(0%)
|
0%
|
220 |
110,000
|
ResMed Common Stock |
|
Michael J. Rider
|
Global General Counsel |
Sale of securities on an exchange or to another person at price $ 217.20 per share. |
03 Jul 2023 |
25 |
5,211
(0%)
|
0%
|
217.2 |
5,430
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 216.27 per share. |
15 Jun 2023 |
1,500 |
253,526
(0%)
|
0%
|
216.3 |
324,405
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 217.39 per share. |
15 Jun 2023 |
5,675 |
436,930
(0%)
|
0%
|
217.4 |
1,233,716
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Jun 2023 |
5,675 |
31,840
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Jun 2023 |
5,675 |
442,605
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 219.79 per share. |
05 Jun 2023 |
1,500 |
89,729
(0%)
|
0%
|
219.8 |
329,685
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Sale of securities on an exchange or to another person at price $ 220.00 per share. |
02 Jun 2023 |
500 |
12,287
(0%)
|
0%
|
220 |
110,000
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 232.85 per share. |
15 May 2023 |
1,500 |
255,026
(0%)
|
0%
|
232.9 |
349,275
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 May 2023 |
5,675 |
37,515
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 232.10 per share. |
15 May 2023 |
5,675 |
436,930
(0%)
|
0%
|
232.1 |
1,317,191
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 May 2023 |
5,675 |
442,605
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 233.13 per share. |
10 May 2023 |
12,574 |
90,942
(0%)
|
0%
|
233.1 |
2,931,395
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 232.05 per share. |
09 May 2023 |
3,426 |
103,516
(0%)
|
0%
|
232.0 |
795,000
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 237.64 per share. |
03 May 2023 |
1,500 |
91,172
(0%)
|
0%
|
237.6 |
356,460
|
ResMed Common Stock |
|
Peter Farrell C.
|
Director |
Sale of securities on an exchange or to another person at price $ 182.66 per share. |
03 May 2023 |
10,935 |
157,404
(0%)
|
0%
|
182.7 |
1,997,434
|
ResMed Common Stock |
|
C. Peter Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 237.17 per share. |
03 May 2023 |
12,600 |
166,896
(0%)
|
0%
|
237.2 |
2,988,375
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Sale of securities on an exchange or to another person at price $ 239.30 per share. |
01 May 2023 |
500 |
12,704
(0%)
|
0%
|
239.3 |
119,650
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Sale of securities on an exchange or to another person at price $ 230.00 per share. |
24 Apr 2023 |
2,000 |
13,204
(0%)
|
0%
|
230 |
460,000
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 224.65 per share. |
17 Apr 2023 |
1,500 |
256,526
(0%)
|
0%
|
224.7 |
336,975
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Apr 2023 |
5,675 |
43,190
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 224.23 per share. |
17 Apr 2023 |
5,675 |
436,900
(0%)
|
0%
|
224.2 |
1,272,526
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
17 Apr 2023 |
5,675 |
442,575
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 218.23 per share. |
03 Apr 2023 |
1,500 |
92,672
(0%)
|
0%
|
218.2 |
327,345
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Sale of securities on an exchange or to another person at price $ 220.00 per share. |
03 Apr 2023 |
500 |
15,204
(0%)
|
0%
|
220 |
110,000
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 206.14 per share. |
15 Mar 2023 |
1,500 |
258,026
(0%)
|
0%
|
206.1 |
309,210
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Gift of securities by or to the insider at price $ 0.00 per share. |
15 Mar 2023 |
1,919 |
259,526
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 206.95 per share. |
15 Mar 2023 |
5,675 |
436,900
(0%)
|
0%
|
207.0 |
1,174,451
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Mar 2023 |
5,675 |
442,575
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Mar 2023 |
5,675 |
48,865
|
-
|
|
-
|
ResMed Common Stock Options |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 216.69 per share. |
03 Mar 2023 |
1,500 |
94,172
(0%)
|
0%
|
216.7 |
325,035
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Sale of securities on an exchange or to another person at price $ 220.00 per share. |
03 Mar 2023 |
1,000 |
15,704
(0%)
|
0%
|
220 |
220,000
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 215.22 per share. |
17 Feb 2023 |
10,000 |
106,880
(0%)
|
0%
|
215.2 |
2,152,196
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 213.50 per share. |
15 Feb 2023 |
1,500 |
261,445
(0%)
|
0%
|
213.5 |
320,250
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Feb 2023 |
5,675 |
442,575
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 214.83 per share. |
15 Feb 2023 |
5,675 |
436,900
(0%)
|
0%
|
214.8 |
1,219,144
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Feb 2023 |
5,675 |
54,540
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 215.00 per share. |
13 Feb 2023 |
4,000 |
116,880
(0%)
|
0%
|
215 |
860,000
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 224.50 per share. |
03 Feb 2023 |
1,500 |
95,672
(0%)
|
0%
|
224.5 |
336,750
|
ResMed Common Stock |
|
Karen Drexler
|
Director |
Sale of securities on an exchange or to another person at price $ 226.58 per share. |
02 Feb 2023 |
594 |
7,987
(0%)
|
0%
|
226.6 |
134,589
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 220.43 per share. |
17 Jan 2023 |
1,500 |
226,208
(0%)
|
0%
|
220.4 |
330,645
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Jan 2023 |
5,675 |
60,215
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
17 Jan 2023 |
5,675 |
442,575
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 224.36 per share. |
17 Jan 2023 |
5,675 |
436,900
(0%)
|
0%
|
224.4 |
1,273,269
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 210.07 per share. |
03 Jan 2023 |
1,500 |
97,172
(0%)
|
0%
|
210.1 |
315,105
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Dec 2022 |
5,675 |
65,890
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 215.63 per share. |
15 Dec 2022 |
5,675 |
436,900
(0%)
|
0%
|
215.6 |
1,223,727
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Dec 2022 |
5,675 |
442,575
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 229.81 per share. |
05 Dec 2022 |
1,500 |
98,672
(0%)
|
0%
|
229.8 |
344,715
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Gift of securities by or to the insider at price $ 0.00 per share. |
25 Nov 2022 |
7,300 |
100,172
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
25 Nov 2022 |
683 |
12,540
|
-
|
|
-
|
ResMed Common Stock Options |
|
David B. Pendarvis
|
Chief Administrative Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. |
25 Nov 2022 |
683 |
107,472
(0%)
|
0%
|
146.3 |
99,950
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. |
23 Nov 2022 |
19,425 |
53,556
(0%)
|
0%
|
224.4 |
4,358,970
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
23 Nov 2022 |
32,795 |
72,981
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
23 Nov 2022 |
14,577 |
120,880
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
23 Nov 2022 |
12,389 |
113,700
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. |
23 Nov 2022 |
6,911 |
106,789
(0%)
|
0%
|
224.4 |
1,550,828
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. |
23 Nov 2022 |
33,239 |
436,900
(0%)
|
0%
|
224.4 |
7,458,832
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
23 Nov 2022 |
56,115 |
470,139
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. |
23 Nov 2022 |
4,318 |
16,704
(0%)
|
0%
|
224.4 |
968,959
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
23 Nov 2022 |
7,288 |
21,022
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Justin Leong
|
President, Asia Latin America |
Sale of securities on an exchange or to another person at price $ 229.50 per share. |
22 Nov 2022 |
3,777 |
59,817
(0%)
|
0%
|
229.5 |
866,820
|
ReMed Common Stock |
|
Justin Leong
|
President, Asia Latin America |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
22 Nov 2022 |
15,000 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Justin Leong
|
President, Asia Latin America |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
22 Nov 2022 |
6,924 |
66,741
(0%)
|
0%
|
|
0
|
ReMed Common Stock |
|
Justin Leong
|
President, Asia Latin America |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
22 Nov 2022 |
15,000 |
63,594
(0%)
|
0%
|
57.8 |
866,400
|
ReMed Common Stock |
|
Lucile Blaise
|
President, Sleep & RC Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. |
21 Nov 2022 |
78 |
6,627
(0%)
|
0%
|
224.4 |
17,503
|
ResMed Common Stock |
|
Lucile Blaise
|
President, Sleep & RC Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. |
21 Nov 2022 |
75 |
6,552
(0%)
|
0%
|
224.4 |
16,830
|
ResMed Common Stock |
|
Lucile Blaise
|
President, Sleep & RC Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. |
21 Nov 2022 |
114 |
6,705
(0%)
|
0%
|
224.4 |
25,582
|
ResMed Common Stock |
|
Richard Sulpizio
|
Director |
|
18 Nov 2022 |
1,122 |
14,945
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
1,122 |
179,496
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Ronald R. Taylor
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
1,122 |
20,847
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Carol J. Burt
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
1,122 |
2,078
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Karen Drexler
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
1,122 |
8,581
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Harjit Gill
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
1,122 |
7,266
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Witte Jan De
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
1,122 |
6,111
(0%)
|
0%
|
|
0
|
ReMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
31,649 |
31,649
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
36,569 |
36,569
|
-
|
|
-
|
ResMed Common Stock Options |
|
Justin Leong
|
President, Asia Latin America |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
9,973 |
9,973
|
-
|
|
-
|
ResMed Common Stock Options |
|
Kaushik Ghoshal
|
President, SaaS Business |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
7,314 |
7,314
|
-
|
|
-
|
ResMed Common Stock Options |
|
John Hernandez
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
1,122 |
2,078
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Desney Tan
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Nov 2022 |
1,122 |
2,078
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Lucile Blaise
|
President, Sleep & RC Business |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Nov 2022 |
2,410 |
2,410
|
-
|
|
-
|
ResMed Common Stock Options |
|
Lucile Blaise
|
President, Sleep & RC Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
15 Nov 2022 |
169 |
6,819
(0%)
|
0%
|
225.2 |
38,055
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 222.07 per share. |
15 Nov 2022 |
11,280 |
40,186
(0%)
|
0%
|
222.1 |
2,504,939
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Nov 2022 |
16,888 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Nov 2022 |
1,144 |
16,888
|
-
|
|
-
|
ResMed Common Stock Options |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. |
15 Nov 2022 |
16,888 |
51,466
(0%)
|
0%
|
58.2 |
983,557
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. |
15 Nov 2022 |
1,144 |
34,578
(0%)
|
0%
|
58.2 |
66,627
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Nov 2022 |
5,675 |
71,565
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Nov 2022 |
5,675 |
419,699
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 224.64 per share. |
15 Nov 2022 |
5,675 |
414,024
(0%)
|
0%
|
224.6 |
1,274,837
|
ResMed Common Stock |
|
Lucile Blaise
|
President, Sleep & RC Business |
Sale of securities on an exchange or to another person at price $ 225.18 per share. |
15 Nov 2022 |
169 |
7,335
(0%)
|
0%
|
225.2 |
38,055
|
ResMed Common Stock |
|
Lucile Blaise
|
President, Sleep & RC Business |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 225.18 per share. |
15 Nov 2022 |
516 |
7,504
(0%)
|
0%
|
225.2 |
116,193
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
11 Nov 2022 |
128 |
178,374
(0%)
|
0%
|
225.2 |
28,823
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
11 Nov 2022 |
760 |
33,434
(0%)
|
0%
|
225.2 |
171,137
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
11 Nov 2022 |
945 |
34,194
(0%)
|
0%
|
225.2 |
212,795
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
11 Nov 2022 |
450 |
101,927
(0%)
|
0%
|
225.2 |
101,331
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
11 Nov 2022 |
279 |
101,311
(0%)
|
0%
|
225.2 |
62,825
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
11 Nov 2022 |
337 |
101,590
(0%)
|
0%
|
225.2 |
75,886
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
11 Nov 2022 |
3,038 |
414,024
(0%)
|
0%
|
225.2 |
684,097
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
11 Nov 2022 |
3,233 |
417,062
(0%)
|
0%
|
225.2 |
728,007
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
11 Nov 2022 |
2,359 |
420,295
(0%)
|
0%
|
225.2 |
531,200
|
ResMed Common Stock |
|
Harjit Gill
|
Director |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.17 per share. |
11 Nov 2022 |
41 |
6,144
(0%)
|
0%
|
225.2 |
9,232
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
11 Nov 2022 |
307 |
14,325
(0%)
|
0%
|
225.2 |
69,130
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. |
11 Nov 2022 |
591 |
13,734
(0%)
|
0%
|
225.2 |
133,081
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Gift of securities by or to the insider at price $ 0.00 per share. |
10 Nov 2022 |
1,000 |
4,090
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 220.83 per share. |
10 Nov 2022 |
4,880 |
0
(0%)
|
0%
|
220.8 |
1,077,650
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Gift of securities by or to the insider at price $ 0.00 per share. |
10 Nov 2022 |
1,000 |
4,880
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 212.02 per share. |
07 Nov 2022 |
4,000 |
106,303
(0%)
|
0%
|
212.0 |
848,068
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 215.23 per share. |
03 Nov 2022 |
1,545 |
102,334
(0%)
|
0%
|
215.2 |
332,530
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Gift of securities by or to the insider at price $ 0.00 per share. |
31 Oct 2022 |
4,550 |
178,502
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Peter C. Farrell
|
Director |
Sale of securities on an exchange or to another person at price $ 221.98 per share. |
31 Oct 2022 |
9,050 |
183,052
(0%)
|
0%
|
222.0 |
2,008,877
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
17 Oct 2022 |
5,675 |
428,245
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 214.58 per share. |
17 Oct 2022 |
5,675 |
422,570
(0%)
|
0%
|
214.6 |
1,217,723
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Oct 2022 |
5,675 |
77,240
|
-
|
|
-
|
ResMed Common Stock Options |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. |
14 Oct 2022 |
1,145 |
29,553
(0%)
|
0%
|
58.2 |
66,685
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
14 Oct 2022 |
16,888 |
18,032
|
-
|
|
-
|
ResMed Common Stock Options |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
14 Oct 2022 |
1,145 |
34,920
|
-
|
|
-
|
ResMed Common Stock Options |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 215.09 per share. |
14 Oct 2022 |
11,355 |
35,086
(0%)
|
0%
|
215.1 |
2,442,298
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. |
14 Oct 2022 |
16,888 |
46,441
(0%)
|
0%
|
58.2 |
983,557
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 220.19 per share. |
03 Oct 2022 |
1,545 |
103,879
(0%)
|
0%
|
220.2 |
340,194
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Sep 2022 |
5,675 |
428,245
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Sep 2022 |
5,675 |
82,915
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 228.96 per share. |
15 Sep 2022 |
5,675 |
422,570
(0%)
|
0%
|
229.0 |
1,299,336
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Gift of securities by or to the insider at price $ 0.00 per share. |
15 Sep 2022 |
1,287 |
227,708
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Sep 2022 |
16,888 |
36,065
|
-
|
|
-
|
ResMed Common Stock Options |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Sep 2022 |
1,145 |
52,953
|
-
|
|
-
|
ResMed Common Stock Options |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. |
15 Sep 2022 |
16,888 |
39,597
(0%)
|
0%
|
58.2 |
983,557
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. |
15 Sep 2022 |
1,145 |
22,709
(0%)
|
0%
|
58.2 |
66,685
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 232.38 per share. |
15 Sep 2022 |
6,000 |
228,995
(0%)
|
0%
|
232.4 |
1,394,280
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 232.51 per share. |
15 Sep 2022 |
11,189 |
28,408
(0%)
|
0%
|
232.5 |
2,601,583
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 216.92 per share. |
06 Sep 2022 |
1,545 |
105,424
(0%)
|
0%
|
216.9 |
335,141
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
18 Aug 2022 |
4,328 |
21,564
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
18 Aug 2022 |
3,847 |
110,273
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
18 Aug 2022 |
1,683 |
106,969
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
18 Aug 2022 |
17,310 |
422,570
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Kaushik Ghoshal
|
President, SaaS Business |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
18 Aug 2022 |
3,366 |
14,628
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 238.09 per share. |
15 Aug 2022 |
5,675 |
405,260
(0%)
|
0%
|
238.1 |
1,351,166
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Aug 2022 |
5,675 |
410,935
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Aug 2022 |
5,675 |
88,590
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 240.66 per share. |
10 Aug 2022 |
2,500 |
106,426
(0%)
|
0%
|
240.7 |
601,650
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
10 Aug 2022 |
2,500 |
108,926
(0%)
|
0%
|
57.8 |
144,400
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
10 Aug 2022 |
2,500 |
0
|
-
|
|
-
|
ResMed Common Stock Options |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 240.72 per share. |
03 Aug 2022 |
1,545 |
105,286
(0%)
|
0%
|
240.7 |
371,912
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
22 Jul 2022 |
2,500 |
113,926
(0%)
|
0%
|
57.8 |
144,400
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
22 Jul 2022 |
2,500 |
108,926
(0%)
|
0%
|
57.8 |
144,400
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
22 Jul 2022 |
2,500 |
2,500
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
22 Jul 2022 |
2,500 |
5,000
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
22 Jul 2022 |
2,500 |
7,500
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 235.00 per share. |
22 Jul 2022 |
7,500 |
106,426
(0%)
|
0%
|
235 |
1,762,500
|
ResMed Common Stock |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
22 Jul 2022 |
2,500 |
111,426
(0%)
|
0%
|
57.8 |
144,400
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Jul 2022 |
5,675 |
410,935
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Jul 2022 |
5,675 |
94,265
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 224.94 per share. |
15 Jul 2022 |
5,675 |
405,260
(0%)
|
0%
|
224.9 |
1,276,517
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 212.33 per share. |
05 Jul 2022 |
1,545 |
106,831
(0%)
|
0%
|
212.3 |
328,050
|
ResMed Common Stock |
|
Richard Sulpizio
|
Director |
|
30 Jun 2022 |
956 |
13,823
(0%)
|
0%
|
|
0
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
15 Jun 2022 |
5,675 |
410,935
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Jun 2022 |
5,675 |
99,940
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 202.54 per share. |
15 Jun 2022 |
5,675 |
405,260
(0%)
|
0%
|
202.5 |
1,149,410
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 209.44 per share. |
03 Jun 2022 |
1,545 |
108,376
(0%)
|
0%
|
209.4 |
323,585
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
16 May 2022 |
5,675 |
410,935
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
16 May 2022 |
5,675 |
105,615
|
-
|
|
-
|
ResMed Common Stock Options |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 196.61 per share. |
16 May 2022 |
5,675 |
405,260
(0%)
|
0%
|
196.6 |
1,115,745
|
ResMed Common Stock |
|
David B. Pendarvis
|
Chief Administrative Officer |
Sale of securities on an exchange or to another person at price $ 200.00 per share. |
03 May 2022 |
1,545 |
109,858
(0%)
|
0%
|
200 |
309,000
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
18 Apr 2022 |
8,000 |
54,098
|
-
|
|
-
|
ResMed Common Stock Options |
|
Robert Andrew Douglas
|
President and COO |
Sale of securities on an exchange or to another person at price $ 233.29 per share. |
18 Apr 2022 |
8,000 |
17,175
(0%)
|
0%
|
233.3 |
1,866,320
|
ResMed Common Stock |
|
Robert Andrew Douglas
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. |
18 Apr 2022 |
8,000 |
25,175
(0%)
|
0%
|
58.2 |
465,920
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 232.41 per share. |
18 Apr 2022 |
5,675 |
405,229
(0%)
|
0%
|
232.4 |
1,318,947
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
18 Apr 2022 |
5,675 |
410,904
(0%)
|
0%
|
57.8 |
327,788
|
ResMed Common Stock |
|
Michael J. Farrell
|
Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
18 Apr 2022 |
5,675 |
111,290
|
-
|
|
-
|
ResMed Common Stock Options |
|
Brett A. Sandercock
|
Chief Financial Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. |
11 Apr 2022 |
2,500 |
108,854
(0%)
|
0%
|
57.8 |
144,400
|
ResMed Common Stock |